Background Diabetic macular oedema (DMO) is a common complication of diabetic
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …

Aptamers are widely applied to diagnosis and therapy because of their targeting. However,
the current progress of research into aptamers for the treatment of eye disorders has not …

Purpose To evaluate the efficacy, safety, and injection frequency of vascular endothelial
growth factor (VEGF) inhibitors as used in clinical practice for the treatment of diabetic …

Diabetic macular edema (DME), characterized by exudative fluid accumulation in the
macula, is the most common form of sight-threatening retinopathy in patients with diabetes …

Purpose: To determine whether combining measures of retinal structure and function
predicts need for intervention for diabetic retinopathy (DR) better than either modality alone …

Purpose Antivascular endothelial growth factor agents are increasingly used in diabetic
macular oedema (DME); however, there are few studies exploring their use in DME in real …

Purpose: To report the real-world effectiveness and safety of ranibizumab 0.5 mg in patients
with visual impairment due to diabetic macular edema (DME). Methods: This is a French, 36 …

Objective To describe the management of diabetic macular oedema (DME) patients from the
entire French population between 2012 and 2018. Methods In this retrospective longitudinal …

Purpose To describe the treatment patterns and the predictors of different treatment
standards in recently diagnosed diabetic macular edema (DME) patients in a nationally …

The objective of this study was to identify biomarkers that predict a future need for anti-VEGF
therapy in diabetic retinopathy (DR). Eyes with DR that underwent ultra-widefield …